Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A

The Phase 3 A‐LONG study demonstrated the safety and efficacy of rFVIIIFc for the control and prevention of bleeding episodes in severe haemophilia A.

[1]  D. Perry,et al.  Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  I. Nestorov,et al.  Population pharmacokinetics of recombinant factor VIII Fc fusion protein , 2015, Clinical pharmacology in drug development.

[3]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[4]  M. Ozelo,et al.  Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  H. ten Cate,et al.  The impact of blood coagulability on atherosclerosis and cardiovascular disease , 2012, Journal of thrombosis and haemostasis : JTH.

[7]  P. Fogarty,et al.  Biological rationale for new drugs in the bleeding disorders pipeline. , 2011, Hematology. American Society of Hematology. Education Program.

[8]  Max E Valentinuzzi,et al.  SAFETY AND EFFICACY , 2010 .

[9]  L. Valentino,et al.  Blood‐induced joint disease: the pathophysiology of hemophilic arthropathy , 2010, Journal of thrombosis and haemostasis : JTH.

[10]  R. Liesner,et al.  A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A , 2010, British journal of haematology.

[11]  S. Pipe.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A , 2009, Biologics : targets & therapy.

[12]  P. Mannucci,et al.  Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[14]  H. Ehrlich,et al.  Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. , 2009, Expert opinion on biological therapy.

[15]  A. Iorio,et al.  Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting , 2007, Thrombosis and Haemostasis.

[16]  M. Cushman.  Inherited risk factors for venous thrombosis. , 2005, Hematology. American Society of Hematology. Education Program.

[17]  M. Manco‐Johnson,et al.  Barriers to compliance with prophylaxis therapy in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  C. Kessler.  ‘Dose requirement for replacement therapy in hemophilia A’ , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  D. Choudhury,et al.  DOUBLE-BLIND CONTROLLED TRIAL OF THREE DOSAGE REGIMENS IN TREATMENT OF HÆMARTHROSES IN HÆMOPHILIA A , 1980, The Lancet.

[20]  D. Choudhury,et al.  Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. , 1980, The Lancet.

[21]  S. Erill,et al.  Letter: Hereditary angioneurotic oedema. , 1974, Lancet.